First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study

Anticancer Res. 2017 Mar;37(3):1403-1407. doi: 10.21873/anticanres.11462.

Abstract

Aim: To assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER)2-negative metastatic breast cancer (mBC) at a single centre with a homogenous standard-of-care.

Patients and methods: Information on patient and disease characteristics, efficacy, and safety was extracted from computer-based records of all patients receiving first-line bevacizumab-paclitaxel at the Curie Institute, Paris, France, between 2008 and 2011.

Results: Median progression-free survival in the 116 treated patients was 13.2 months; median overall survival was 38.4 months. Corresponding values were 9.0 and 18.8 months, respectively, in patients with triple-negative mBC, and 19.4 and 58.8 months, respectively, in patients receiving maintenance endocrine therapy. No new safety signals were seen.

Conclusion: Outcomes in patients treated with bevacizumab-paclitaxel at our center were consistent with efficacy in prospective clinical trials, with notable activity in poor-prognosis disease. Maintenance endocrine or oral therapy with bevacizumab after paclitaxel discontinuation was associated with long-term disease control.

Keywords: Bevacizumab; HER2-negative; first-line; metastatic breast cancer; paclitaxel.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Disease-Free Survival
  • Female
  • France
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Paclitaxel / administration & dosage*
  • Prognosis
  • Prospective Studies
  • Receptor, ErbB-2 / metabolism*
  • Retrospective Studies
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / metabolism*

Substances

  • Bevacizumab
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Paclitaxel